REGN is up 106.5% in the last nine months, but already down nearly 2% in June
Over the past two weeks, we've been exploring some of the best S&P 500 stocks to own in June,
historically. Now, with help from Schaeffer's Senior Quantitative Analyst Rocky White, we'll shift gears and focus on 25 of the worst performers this month, looking back over the past 10 years. One notable name on the list is Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Though the biotech has been charging up the charts lately, hitting a record high of $618.71 on June 2, history shows that it might be time for REGN to take a breather. In the last decade, Regeneron Pharmaceuticals has only seen three positive one-month
returns in June, averaging a loss of 4.6%. This is good for worst on the list and makes REGN the only biotechnology stock present.
Digging deeper on the charts, REGN is up an impressive 106.5% in the past nine months, recently pushing past the $600 region for the first time in over four years. However, the stock seems to have lost steam just below its aforementioned all-time
high and is down 1.8% so far in June after four straight months of gains.
Analysts are split on Regeneron stock, with 11 sporting a "strong buy," compared to 10 at a tepid "hold." Meanwhile, the 12-month consensus price target of $604.88 is just a chip-shot away from current levels, which could lead to price target
cuts, should REGN continue its sideways trajectory.
Though calls are still outweighing puts overall, there has been an unusually heavy appetite for these bearish bets of late. This is per REGN's 50-day put/call ratio of 0.60 at the International Securities Exchange (ISE), Cboe Options Exchange
(CBOE), and NASDAQ OMX PHLX (PHLX) which stands higher than 78% of all other readings from the past year.